NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ALT

Altimmune Inc

Jul 09 • 04:00PM ET

4.74

Dollar change +0.16
Percentage change 3.49	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: VTI IWM VXF XBI IWO IBB VTWO FESM VHT OZEM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.25	Insider Own	1.04%	Shs Outstand	81.11M	Perf Week	12.06%
Market Cap	384.45M	Forward P/E	-	EPS next Y	-1.57	Insider Trans	1.32%	Shs Float	80.26M	Perf Month	-15.66%
Enterprise Value	236.17M	PEG	-	EPS next Q	-0.31	Inst Own	47.37%	Short Float	30.40%	Perf Quarter	19.10%
Income	-90.24M	P/S	19222.36	EPS this Y	5.69%	Inst Trans	-5.65%	Short Ratio	4.58	Perf Half Y	-34.71%
Sales	0.02M	P/B	2.59	EPS next Y	-24.49%	ROA	-52.22%	Short Interest	24.40M	Perf YTD	-34.26%
Book/sh	1.83	P/C	2.57	EPS next 5Y	0.61%	ROE	-57.28%	52W High	11.16 -57.53%	Perf Year	-28.40%
Cash/sh	1.85	P/FCF	-	EPS past 3/5Y	17.12% 3.48%	ROIC	-62.88%	52W Low	2.90 63.45%	Perf 3Y	-57.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-83.45% -67.83%	Gross Margin	-700.00%	Volatility	8.52% 11.32%	Perf 5Y	-52.31%
Dividend TTM	-	EV/Sales	11808.36	EPS Y/Y TTM	21.09%	Oper. Margin	-490965.00%	ATR (14)	0.64	Perf 10Y	-92.57%
Dividend Ex-Date	Jan 20, 2017	Quick Ratio	15.82	Sales Y/Y TTM	-95.12%	Profit Margin	-451200.00%	RSI (14)	43.78	Recom	1.22
Dividend Gr. 3/5Y	- -	Current Ratio	15.82	EPS Q/Q	24.79%	SMA20	-17.87%	Beta	-0.01	Target Price	22.38
Payout	-	Debt/Eq	0.01	Sales Q/Q	0.00%	SMA50	-15.81%	Rel Volume	0.67	Prev Close	4.58
Employees	59	LT Debt/Eq	0.01	Earnings	May 13 BMO	SMA200	-26.41%	Avg Volume	5.32M	Price	4.74
IPO	Oct 06, 2005	Option/Short	Yes / Yes	EPS/Sales Surpr.	26.12% -	Trades		Volume	3,563,158	Change	3.49%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-28-25	Initiated	William Blair	Mkt Perform
Jan-08-25	Initiated	Stifel	Buy	$18
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30
Oct-09-17	Initiated	Piper Jaffray	Overweight	$6

Show Previous Ratings

Today 07:30AM	Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) (GlobeNewswire)
01:19AM	Altimmune (ALT) Reports Positive Phase 2b Results for Pemvidutide in MASH Trial (Insider Monkey)
Jun-26-25 07:00AM	Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH (GlobeNewswire) -53.18%
Jun-25-25 07:12PM	Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 (GlobeNewswire) +7.23%
Jun-18-25 09:53AM	Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside. (Motley Fool)
07:30AM	Loading…
Jun-13-25 07:30AM	Altimmune Announces Multiple Presentations at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
May-21-25 11:17AM	Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential (Insider Monkey)
May-19-25 07:30AM	Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) (GlobeNewswire)
May-14-25 09:18AM	Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension (TipRanks)
07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-13-25 07:00AM	Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital (GlobeNewswire)
07:00AM	Altimmune Announces First Quarter 2025 Financial Results and Business Update (GlobeNewswire)
May-12-25 01:01PM	Will Healthy Y/Y Revenue Growth Boost Keysight's Q2 Earnings? (Zacks) +7.51%
06:33AM	Doximity Q4 Earnings Likely to Reflect Strong Product Momentum (Zacks)
May-09-25 09:55AM	How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% (Zacks)
07:30AM	Loading…
May-08-25 07:30AM	Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress (GlobeNewswire) +8.21%
May-06-25 07:30AM	Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 (GlobeNewswire) -7.37%
May-01-25 07:30AM	Altimmune to Present at Upcoming EASL International Liver Congress 2025 (GlobeNewswire)
Apr-30-25 07:30AM	Altimmune to Participate in the Citizens Life Sciences Conference (GlobeNewswire)
04:51AM	Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
04:51AM	Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? (Motley Fool)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Mar-22-25 06:44AM	Buying These Dirt-Cheap Stocks Could Be a Brilliant Move (Motley Fool)
Mar-19-25 04:33PM	Altimmune, Inc. (ALT): The Best Short Squeeze Stock to Buy According to Analysts (InsiderMonkey)
Mar-06-25 07:30AM	Altimmune to Host Virtual R&D Day on March 13, 2025 (GlobeNewswire)
Mar-03-25 07:30AM	Altimmune to Participate in the Leerink Global Healthcare Conference (GlobeNewswire) -9.92%
Feb-27-25 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update (GlobeNewswire) +8.08%
Feb-25-25 07:30AM	Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors (GlobeNewswire)
Feb-20-25 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025 (GlobeNewswire)
Jan-29-25 07:30AM	Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
03:39PM	Loading…
Dec-28-24 03:39PM	Jim Cramer on Altimmune, Inc. (ALT): and#8216;Healthcare Is So Out Of Fashion' (Insider Monkey)
Dec-19-24 07:30AM	Altimmune Added to Nasdaq Biotechnology Index (GlobeNewswire)
Dec-17-24 08:13PM	Lightning Round: Ford's warranty problems will come back to haunt it, says Jim Cramer (CNBC TV) -6.67% -5.95%
Dec-03-24 06:22PM	Altimmune CEO on what's next for its experimental obesity drug (CNBC TV) +12.06%
Dec-02-24 07:30AM	Altimmune to Present at the Cachexia Regulatory and Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders (GlobeNewswire)
07:30AM	Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders (GlobeNewswire)
Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -15.59%
07:30AM	Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt (GlobeNewswire)
Jun-24-24 06:02PM	Crypto under pressure, Good Buy or Goodbye: Market Domination (Yahoo Finance Video) +11.39%
03:52PM	Altimmune reports positive results in weight-loss drug trial (Yahoo Finance Video)
11:13AM	BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms (InvestorPlace)
10:56AM	ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings (InvestorPlace)
Jun-23-24 01:45PM	Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
Jun-22-24 04:45PM	Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions (GlobeNewswire)
Jun-21-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) +7.91%
Jun-20-24 07:30AM	Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways (GlobeNewswire)
Jun-18-24 07:30AM	Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
Jun-12-24 10:00AM	3 Stocks Quietly Preparing for a 10X Surge: June Edition (InvestorPlace)
Jun-05-24 07:00AM	Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-29-24 07:31AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress 2024 (GlobeNewswire)
May-27-24 02:56PM	The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop (InvestorPlace)
May-23-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) -6.34%
May-21-24 02:53PM	Altimmune, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ALT (GlobeNewswire)
09:00AM	Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) (PR Newswire)
May-20-24 03:01PM	Robbins LLP Urges Altimmune, Inc. (ALT) Stockholders With Large Losses to Contact the Firm for Information About Their Rights (Business Wire)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace) -10.00%
May-15-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire) +13.43%
May-14-24 12:47PM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights ALT (GlobeNewswire) +6.11%
May-10-24 03:58PM	Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.48%
May-09-24 11:57AM	ALT Stock Earnings: Altimmune Beats EPS for Q1 2024 (InvestorPlace) +7.82%
07:00AM	Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:50AM	Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire)
May-07-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-02-24 07:30AM	Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (GlobeNewswire)
May-01-24 07:30AM	Altimmune to Participate at Two Upcoming Conferences (GlobeNewswire) +7.94%
Apr-25-24 05:24PM	Altimmune Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire)
Mar-29-24 12:00PM	Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-28-24 10:49AM	Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.51%
Mar-27-24 06:29PM	A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugs (Quartz)
11:53AM	ALT Stock Earnings: Altimmune Beats EPS for Q4 2023 (InvestorPlace)
07:58AM	Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans (FierceBiotech.com)
07:00AM	Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-20-24 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 (GlobeNewswire) +6.86%
Feb-26-24 09:26AM	Why Is Altimmune (ALT) Stock Up 14% Today? (InvestorPlace) +23.04%
Feb-20-24 10:26AM	Altimmune (ALT) to Report Q4 Earnings: What's in the Cards? (Zacks)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sohn Catherine A.	Director	Mar 17 '25	Buy	5.78	1,000	5,784	1,000	Mar 18 04:15 PM
WEAVER GREGORY L	Chief Financial Officer	Mar 13 '25	Buy	5.20	10,000	51,996	10,000	Mar 14 07:27 AM
Garg Vipin K	President and CEO	Feb 02 '25	Option Exercise	0.00	18,950	0	363,364	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Feb 01 '25	Option Exercise	0.00	16,545	0	351,645	Feb 03 08:50 PM
Garg Vipin K	President and CEO	Jan 30 '25	Option Exercise	0.00	26,775	0	342,696	Feb 03 08:50 PM
Harris Matthew Scott	Chief Medical Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	84,564	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	78,898	Feb 03 08:48 PM
Harris Matthew Scott	Chief Medical Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	74,000	Feb 03 08:48 PM
Roberts M Scot	Chief Scientific Officer	Feb 02 '25	Option Exercise	0.00	7,775	0	75,536	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Feb 01 '25	Option Exercise	0.00	6,166	0	69,562	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '25	Option Exercise	0.00	9,275	0	62,921	Feb 03 08:43 PM
Roberts M Scot	Chief Scientific Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	57,910	Jan 28 09:06 PM
Jordt Raymond M	Chief Business Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	36,150	Jan 28 09:05 PM
Harris Matthew Scott	Chief Medical Officer	Jan 25 '25	Option Exercise	0.00	14,600	0	69,719	Jan 28 09:05 PM
Garg Vipin K	President and CEO	Jan 25 '25	Option Exercise	0.00	42,050	0	334,078	Jan 28 09:04 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '25	Option Exercise	0.00	9,375	0	24,035	Jan 03 04:40 PM
Drutz David	Director	Aug 19 '24	Option Exercise	2.55	41,750	106,375	63,708	Aug 20 06:05 PM
Drutz David	Director	Aug 19 '24	Sale	6.90	16,011	110,547	41,958	Aug 20 06:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALT

Altimmune Inc

Upgrade your FINVIZ experience